New Web Based Data Entry System!
On June 2, 2014, a new, totally revamped version of the INTERMACS (adults) web based data entry system went live (please see below for a complete description of the details of the new system). During this initial “burn in” phase of the new system, many of you have identified issues (bugs) with both the new log-in system and the data entry system itself. We greatly appreciate your patience during this initial period and we sincerely want to minimize your frustrations. If you have any issues with any aspect of the new log-in process, please contact Chase Lenderman (205-975-3902, chaseter@uab.edu) or Maceo Cleggett (205-975-3901, mclegg@uab.edu). If you have any issues with the data entry system, please continue to contact your INTERMACS nurse monitor. We will answer phone calls as soon as possible and we will respond to emails the same day or early the next day. Our goal is to provide the most useful INTERMACS system possible while quickly responding and resolving identified issues. Thank you.

 
August 11, 2014: Web Based Data Entry System Update
 
The transition to the new 4.0 protocol and the new web based data entry (WBDE) systems continue to make good progress. We are addressing data entry “bugs” and ask users to notify us if issues with the new system are identified. We continue to appreciate everyone’s patience as we go through this transition.
 
Intermacs for adults: Launch of the new Intermacs WBDE system occurred June 2, 2014.

  • 129 hospitals have approved Protocol 4.0
  • 262 users have successfully logged into the new WBDE system

 
Pedimacs for pediatric patients: On July 31, 2014 the new Pedimacs WBDE system was launched. 

  • 61 centers have indicated they can enroll patients in Pedimacs
  • 52 of 61 centers have approval for Protocol 4.0

 


Intermacs/Pedimacs has undergone several changes recently which will be implemented June 1, 2014. The primary change reflects the transition of Intermacs from a research registry to a Quality Improvement registry which we believe will no longer require Informed Consent. Below is a list of changes, new documents and suggestions for a smooth transition. Please contact the Intermacs Data Coordinating Center if you have any questions.

• New Protocol
            The new Protocol 4.0 is to be used for both Intermacs and Pedimacs.

• New Users' Guides
            The Users' Guide has been updated and separated into two Guides,
            one for Intermacs and one for Pedimacs.

• Waiver of Informed Consent and Authorization
            Intermacs has provided a Justification letter describing why we
            believe a waiver of consent and authorization is appropriate for
            the registry

• List of Changes
            A list of Additions and Deletions describing the changes is available.

• Revised Data Collection Forms
            New Intermacs Data Collection Forms are available. Pedimacs Data
            Collection Forms will be available in July.

• New security measures
            A two-factor authentication application which uses a phone or hardware
            token will be used to verify the user’s identity. Instructions will be
            provided to Intermacs members.
 



The Interagency Registry for Mechanically Assisted Circulatory Support is a North American registry established in 2005 for patients who are receiving mechanical circulatory support device therapy to treat advanced heart failure. Intermacs®was established as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA), clinicians, scientists and industry representatives in conjunction with Dr. James K. Kirklin and the University of Alabama at Birmingham.

Intermacs® is a prospective registry that collects clinical data, including follow up, essentially as it happens.  Post implant follow up data is collected at 1 week, 1 month, 3 months, 6 months and every 6 months thereafter.  Major outcomes after implant, e.g. death, explant, rehospitalization and adverse events, are entered as they occur and also as part of the defined follow-up scheduled intervals.

Intermacs® provides contemporary data to demonstrate the continued progress of outcomes, with additional insight into appropriate risk stratification and patient selection.  Death, transplant, and explant are the major discrete endpoints recorded.

Complex endpoints that include the patient’s level of function and quality of life, critical to the evaluation of current MCSD therapy, for which improvements in both survival and function have been compelling. These indices are becoming increasingly important as the survival improves, and new devices will be compared for outcomes beyond survival.

Sponsored by The National Heart, Lung and Blood Institute (NHLI) and housed at the University of Alabama at Birmingham, Intermacs® launched June 2006 with 15 participating hospitals within the United States. The registry has quickly grown to include the majority of VAD centers in the U.S, is recognized as the Joint Commission mandated registry for all U.S. centers implanting VADS for destination therapy and now has expanded to include all interested hospitals the United States and Canada. 



Intermacs® is sensitive to site and participant confidentiality. Please use a secure e-mail to communicate confidential information with the Data Coordinating Center.  If you do not have a secure e-mail available, contact the Intermacs® Data Coordinating Center at intermacs@uab.edu and request access to the Intermacs® secure e-mail.

This project has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract Number HHSN268201100025C.